Skip to main content
Top
Published in: BMC Medical Research Methodology 1/2024

Open Access 01-12-2024 | Endometrial Cancer | Research

Weibull parametric model for survival analysis in women with endometrial cancer using clinical and T2-weighted MRI radiomic features

Authors: Xingfeng Li, Diana Marcus, James Russell, Eric O. Aboagye, Laura Burney Ellis, Alexander Sheeka, Won-Ho Edward Park, Nishat Bharwani, Sadaf Ghaem-Maghami, Andrea G. Rockall

Published in: BMC Medical Research Methodology | Issue 1/2024

Login to get access

Abstract

Background

Semiparametric survival analysis such as the Cox proportional hazards (CPH) regression model is commonly employed in endometrial cancer (EC) study. Although this method does not need to know the baseline hazard function, it cannot estimate event time ratio (ETR) which measures relative increase or decrease in survival time. To estimate ETR, the Weibull parametric model needs to be applied. The objective of this study is to develop and evaluate the Weibull parametric model for EC patients’ survival analysis.

Methods

Training (n = 411) and testing (n = 80) datasets from EC patients were retrospectively collected to investigate this problem. To determine the optimal CPH model from the training dataset, a bi-level model selection with minimax concave penalty was applied to select clinical and radiomic features which were obtained from T2-weighted MRI images. After the CPH model was built, model diagnostic was carried out to evaluate the proportional hazard assumption with Schoenfeld test. Survival data were fitted into a Weibull model and hazard ratio (HR) and ETR were calculated from the model. Brier score and time-dependent area under the receiver operating characteristic curve (AUC) were compared between CPH and Weibull models. Goodness of the fit was measured with Kolmogorov-Smirnov (KS) statistic.

Results

Although the proportional hazard assumption holds for fitting EC survival data, the linearity of the model assumption is suspicious as there are trends in the age and cancer grade predictors. The result also showed that there was a significant relation between the EC survival data and the Weibull distribution. Finally, it showed that Weibull model has a larger AUC value than CPH model in general, and it also has smaller Brier score value for EC survival prediction using both training and testing datasets, suggesting that it is more accurate to use the Weibull model for EC survival analysis.

Conclusions

The Weibull parametric model for EC survival analysis allows simultaneous characterization of the treatment effect in terms of the hazard ratio and the event time ratio (ETR), which is likely to be better understood. This method can be extended to study progression free survival and disease specific survival.

Trial registration

ClinicalTrials.gov NCT03543215, https://​clinicaltrials.​gov/​, date of registration: 30th June 2017.
Appendix
Available only for authorised users
Literature
1.
go back to reference Crosbie EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, Powell ME, Singh N. Endometrial cancer. Lancet. 2022;399(10333):1412–28.CrossRefPubMed Crosbie EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, Powell ME, Singh N. Endometrial cancer. Lancet. 2022;399(10333):1412–28.CrossRefPubMed
2.
go back to reference Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457–81.CrossRef Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457–81.CrossRef
3.
go back to reference Cox DR. Regression models and Life-Tables. J Roy Stat Soc: Ser B (Methodol). 1972;34(2):187–202.CrossRef Cox DR. Regression models and Life-Tables. J Roy Stat Soc: Ser B (Methodol). 1972;34(2):187–202.CrossRef
5.
go back to reference Tejerizo-García Á, Jiménez-López JS, Muñoz-González JL, Bartolomé-Sotillos S, Marqueta-Marqués L, López-González G. Gómez JFP-R: overall survival and disease-free survival in endometrial cancer: prognostic factors in 276 patients. OncoTargets Therapy 2013:1305–13. Tejerizo-García Á, Jiménez-López JS, Muñoz-González JL, Bartolomé-Sotillos S, Marqueta-Marqués L, López-González G. Gómez JFP-R: overall survival and disease-free survival in endometrial cancer: prognostic factors in 276 patients. OncoTargets Therapy 2013:1305–13.
6.
go back to reference Li X, Marcus D, Russell J, Aboagye EO, Ellis LB, Sheeka A, Park WE, Bharwani N, Ghaem-Maghami S, Rockall AG. An Integrated Clinical-MR Radiomics Model to Estimate Survival Time in patients with Endometrial Cancer. J Magn Reson Imaging 2022. Li X, Marcus D, Russell J, Aboagye EO, Ellis LB, Sheeka A, Park WE, Bharwani N, Ghaem-Maghami S, Rockall AG. An Integrated Clinical-MR Radiomics Model to Estimate Survival Time in patients with Endometrial Cancer. J Magn Reson Imaging 2022.
7.
go back to reference Bedir A, Abera SF, Vordermark D, Medenwald D. Socioeconomic disparities in endometrial cancer survival in Germany: a survival analysis using population-based cancer registry data. J Cancer Res Clin Oncol. 2022;148(5):1087–95.CrossRefPubMedCentralPubMed Bedir A, Abera SF, Vordermark D, Medenwald D. Socioeconomic disparities in endometrial cancer survival in Germany: a survival analysis using population-based cancer registry data. J Cancer Res Clin Oncol. 2022;148(5):1087–95.CrossRefPubMedCentralPubMed
8.
go back to reference Snapinn SM, Jiang Q, Iglewicz B. Illustrating the impact of a time-varying covariate with an Extended Kaplan-Meier Estimator. Am Stat. 2005;59(4):301–7.CrossRef Snapinn SM, Jiang Q, Iglewicz B. Illustrating the impact of a time-varying covariate with an Extended Kaplan-Meier Estimator. Am Stat. 2005;59(4):301–7.CrossRef
9.
go back to reference Bradburn MJ, Clark TG, Love SB, Altman DG. Survival analysis part II: multivariate data analysis – an introduction to concepts and methods. Br J Cancer. 2003;89(3):431–6.CrossRefPubMedCentralPubMed Bradburn MJ, Clark TG, Love SB, Altman DG. Survival analysis part II: multivariate data analysis – an introduction to concepts and methods. Br J Cancer. 2003;89(3):431–6.CrossRefPubMedCentralPubMed
10.
go back to reference Nardi A, Schemper M. Comparing Cox and parametric models in clinical studies. Stat Med. 2003;22(23):3597–610.CrossRefPubMed Nardi A, Schemper M. Comparing Cox and parametric models in clinical studies. Stat Med. 2003;22(23):3597–610.CrossRefPubMed
11.
go back to reference Plana D, Fell G, Alexander BM, Palmer AC, Sorger PK. Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects. Nat Commun. 2022;13(1):873.CrossRefPubMedCentralPubMed Plana D, Fell G, Alexander BM, Palmer AC, Sorger PK. Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects. Nat Commun. 2022;13(1):873.CrossRefPubMedCentralPubMed
12.
13.
go back to reference Aalen O, Borgan O, Gjessing H. Survival and event history analysis: a process point of view. Springer Science & Business Media; 2008. Aalen O, Borgan O, Gjessing H. Survival and event history analysis: a process point of view. Springer Science & Business Media; 2008.
14.
go back to reference Li X, Dessi M, Marcus D, Russell J, Aboagye EO, Ellis LB, Sheeka A, Park W-HE, Bharwani N, Ghaem-Maghami S, et al. Prediction of deep myometrial infiltration, clinical risk category, histological type, and Lymphovascular Space Invasion in Women with Endometrial Cancer based on clinical and T2-Weighted MRI Radiomic features. Cancers. 2023;15(8):2209.CrossRefPubMedCentralPubMed Li X, Dessi M, Marcus D, Russell J, Aboagye EO, Ellis LB, Sheeka A, Park W-HE, Bharwani N, Ghaem-Maghami S, et al. Prediction of deep myometrial infiltration, clinical risk category, histological type, and Lymphovascular Space Invasion in Women with Endometrial Cancer based on clinical and T2-Weighted MRI Radiomic features. Cancers. 2023;15(8):2209.CrossRefPubMedCentralPubMed
15.
go back to reference Klein JP, Moeschberger ML. Survival analysis: techniques for censored and truncated data. Volume 1230. Springer; 2003. Klein JP, Moeschberger ML. Survival analysis: techniques for censored and truncated data. Volume 1230. Springer; 2003.
16.
go back to reference Carroll KJ. On the use and utility of the Weibull model in the analysis of survival data. Control Clin Trials. 2003;24(6):682–701.CrossRefPubMed Carroll KJ. On the use and utility of the Weibull model in the analysis of survival data. Control Clin Trials. 2003;24(6):682–701.CrossRefPubMed
17.
go back to reference Haile SR. Weibull AFT Regression Functions in R. In. R help document; 2022. Haile SR. Weibull AFT Regression Functions in R. In. R help document; 2022.
19.
go back to reference Breheny P, Huang J. Penalized methods for bi-level variable selection. Stat its Interface. 2009;2(3):369.CrossRef Breheny P, Huang J. Penalized methods for bi-level variable selection. Stat its Interface. 2009;2(3):369.CrossRef
20.
go back to reference Therneau T. A package for survival analysis in R (R package version 3.5-0). In.: Springer: New York, NY, USA; 2023. Therneau T. A package for survival analysis in R (R package version 3.5-0). In.: Springer: New York, NY, USA; 2023.
21.
go back to reference Kassambara A, Kosinski M, Biecek P, Fabian S. survminer: Drawing Survival Curves using ‘ggplot2’. R package version 03 2017, 1. Kassambara A, Kosinski M, Biecek P, Fabian S. survminer: Drawing Survival Curves using ‘ggplot2’. R package version 03 2017, 1.
22.
go back to reference Broström G. Event History Analysis [R package eha version 2.10. 3]. 2023. Broström G. Event History Analysis [R package eha version 2.10. 3]. 2023.
23.
go back to reference Jackson CH. Flexsurv: a platform for parametric survival modeling in R. J Stat Softw 2016, 70. Jackson CH. Flexsurv: a platform for parametric survival modeling in R. J Stat Softw 2016, 70.
24.
go back to reference Hubeaux S, Rufibach K. SurvRegCensCov: Weibull regression for a right-censored endpoint with a censored covariate. arXiv Preprint arXiv:14020432 2014. Hubeaux S, Rufibach K. SurvRegCensCov: Weibull regression for a right-censored endpoint with a censored covariate. arXiv Preprint arXiv:14020432 2014.
25.
go back to reference Delignette-Muller ML, Dutang C. Fitdistrplus: an R package for fitting distributions. J Stat Softw. 2015;64:1–34.CrossRef Delignette-Muller ML, Dutang C. Fitdistrplus: an R package for fitting distributions. J Stat Softw. 2015;64:1–34.CrossRef
26.
go back to reference Harrell F Jr. rms: Regression Modeling Strategies. R package version 6.2-0. 2021. In.: Accessed 09/12/2021.) Available at: https://CRAN. R-project. org/package = rms; 2023. Harrell F Jr. rms: Regression Modeling Strategies. R package version 6.2-0. 2021. In.: Accessed 09/12/2021.) Available at: https://​CRAN.​ R-project. org/package = rms; 2023.
27.
go back to reference Gerds TA, Ozenne B. riskRegression: risk regression models and prediction scores for survival analysis with competing risks. R package version 2020, 5:2020. Gerds TA, Ozenne B. riskRegression: risk regression models and prediction scores for survival analysis with competing risks. R package version 2020, 5:2020.
29.
go back to reference Grambsch PM, Therneau TM. Proportional hazards tests and Diagnostics based on weighted residuals. Biometrika. 1994;81(3):515–26.CrossRef Grambsch PM, Therneau TM. Proportional hazards tests and Diagnostics based on weighted residuals. Biometrika. 1994;81(3):515–26.CrossRef
30.
go back to reference Haile SR. Weibull AFT Regression Functions in R. 2023. Haile SR. Weibull AFT Regression Functions in R. 2023.
31.
go back to reference Ojara FW, Henrich A, Frances N, Nassar YM, Huisinga W, Hartung N, Geiger K, Holdenrieder S, Joerger M, Kloft C. A prognostic baseline blood biomarker and tumor growth kinetics integrated model in paclitaxel/platinum treated advanced non-small cell lung cancer patients. CPT: Pharmacometrics & Systems Pharmacology, n/a(n/a). Ojara FW, Henrich A, Frances N, Nassar YM, Huisinga W, Hartung N, Geiger K, Holdenrieder S, Joerger M, Kloft C. A prognostic baseline blood biomarker and tumor growth kinetics integrated model in paclitaxel/platinum treated advanced non-small cell lung cancer patients. CPT: Pharmacometrics & Systems Pharmacology, n/a(n/a).
32.
go back to reference Esayas Lelisho M, Akessa GM, Kifle Demissie D, Fikadu Yermosa S, Andargie SA, Tareke SA, Pandey D. Application of Parametric Shared Frailty models to analyze Time-to-death of gastric Cancer patients. J Gastrointest Cancer 2022. Esayas Lelisho M, Akessa GM, Kifle Demissie D, Fikadu Yermosa S, Andargie SA, Tareke SA, Pandey D. Application of Parametric Shared Frailty models to analyze Time-to-death of gastric Cancer patients. J Gastrointest Cancer 2022.
33.
go back to reference Yenilmez İ, Yılmaz E, Kantar YM, Aydın D. Comparison of parametric and semi-parametric models with randomly right-censored data by weighted estimators: two applications in colon cancer and hepatocellular carcinoma datasets. Stat Methods Med Res. 2022;31(2):372–87.CrossRefPubMed Yenilmez İ, Yılmaz E, Kantar YM, Aydın D. Comparison of parametric and semi-parametric models with randomly right-censored data by weighted estimators: two applications in colon cancer and hepatocellular carcinoma datasets. Stat Methods Med Res. 2022;31(2):372–87.CrossRefPubMed
34.
go back to reference Suh K, Carlson JJ, Xia F, Williamson T, Sullivan SD. The potential long-term comparative effectiveness of larotrectinib vs standard of care for treatment of metastatic TRK fusion thyroid cancer, colorectal cancer, and soft tissue sarcoma. J Manag Care Spec Pharm. 2022;28(6):622–30.PubMed Suh K, Carlson JJ, Xia F, Williamson T, Sullivan SD. The potential long-term comparative effectiveness of larotrectinib vs standard of care for treatment of metastatic TRK fusion thyroid cancer, colorectal cancer, and soft tissue sarcoma. J Manag Care Spec Pharm. 2022;28(6):622–30.PubMed
35.
go back to reference Wang P, Li Y, Reddy CK. Machine Learning for Survival Analysis: a Survey. ACM Comput Surv. 2019;51(6):Article110.CrossRef Wang P, Li Y, Reddy CK. Machine Learning for Survival Analysis: a Survey. ACM Comput Surv. 2019;51(6):Article110.CrossRef
36.
go back to reference Lai CD, Min X, Murthy DNP. A modified Weibull distribution. IEEE Trans Reliab. 2003;52(1):33–7.CrossRef Lai CD, Min X, Murthy DNP. A modified Weibull distribution. IEEE Trans Reliab. 2003;52(1):33–7.CrossRef
37.
go back to reference Ip EH, Efendi A, Molenberghs G, Bertoni AG. Comparison of risks of cardiovascular events in the elderly using standard survival analysis and multiple-events and recurrent-events methods. BMC Med Res Methodol. 2015;15:15.CrossRefPubMedCentralPubMed Ip EH, Efendi A, Molenberghs G, Bertoni AG. Comparison of risks of cardiovascular events in the elderly using standard survival analysis and multiple-events and recurrent-events methods. BMC Med Res Methodol. 2015;15:15.CrossRefPubMedCentralPubMed
38.
go back to reference Khan SA, Basharat N. Accelerated failure time models for recurrent event data analysis and joint modeling. Comput Stat. 2022;37(4):1569–97.CrossRef Khan SA, Basharat N. Accelerated failure time models for recurrent event data analysis and joint modeling. Comput Stat. 2022;37(4):1569–97.CrossRef
39.
go back to reference Choi T, Choi S. A fast algorithm for the accelerated failure time model with high-dimensional time-to-event data. J Stat Comput Simul. 2021;91(16):3385–403.CrossRef Choi T, Choi S. A fast algorithm for the accelerated failure time model with high-dimensional time-to-event data. J Stat Comput Simul. 2021;91(16):3385–403.CrossRef
Metadata
Title
Weibull parametric model for survival analysis in women with endometrial cancer using clinical and T2-weighted MRI radiomic features
Authors
Xingfeng Li
Diana Marcus
James Russell
Eric O. Aboagye
Laura Burney Ellis
Alexander Sheeka
Won-Ho Edward Park
Nishat Bharwani
Sadaf Ghaem-Maghami
Andrea G. Rockall
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Medical Research Methodology / Issue 1/2024
Electronic ISSN: 1471-2288
DOI
https://doi.org/10.1186/s12874-024-02234-1

Other articles of this Issue 1/2024

BMC Medical Research Methodology 1/2024 Go to the issue